000			01971 a2200577 4500
005			20250516143918.0
264		0	_c20140519
008			201405s 0 0 eng d
022			_a1463-1326
024	7		_a10.1111/dom.12112 _2doi
040			_aNLM _beng _cNLM
100	1		_aPhielix, E
245	0	0	_aEffects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes. _h[electronic resource]
260			_bDiabetes, obesity & metabolism _cOct 2013
300			_a915-22 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdiponectin _xblood
650	0	4	_aBlood Glucose _xmetabolism
650	0	4	_aBody Mass Index
650	0	4	_aC-Reactive Protein _xmetabolism
650	0	4	_aCyclohexanes _xtherapeutic use
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHepatocytes _xmetabolism
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aInsulin _xtherapeutic use
650	0	4	_aInsulin Resistance
650	0	4	_aLipid Metabolism _xdrug effects
650	0	4	_aLipolysis _xdrug effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNateglinide
650	0	4	_aPhenylalanine _xanalogs & derivatives
650	0	4	_aPioglitazone
650	0	4	_aSulfonylurea Compounds _xtherapeutic use
650	0	4	_aThiazolidinediones _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aBrehm, A
700	1		_aBernroider, E
700	1		_aKrssak, M
700	1		_aAnderwald, C-H
700	1		_aKrebs, M
700	1		_aSchmid, A I
700	1		_aNowotny, P
700	1		_aRoden, M
773	0		_tDiabetes, obesity & metabolism _gvol. 15 _gno. 10 _gp. 915-22
856	4	0	_uhttps://doi.org/10.1111/dom.12112 _zAvailable from publisher's website
999			_c22658404 _d22658404